Expert Insights Into the Biosafety of Oncolytic Immunotherapies and Their Combination With Immune Checkpoint Inhibitors
Do you know how the biosafety risks of oncolytic immunotherapies and their combination with immune checkpoint inhibitors can be mitigated?
Credit available for this activity expires: 6/22/24
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/993479?ecd=bdc_podcast_libsyn_mscpedu
Create your
podcast in
minutes
It is Free